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between pre-eSRT PSA level and BCR-free survival rate at 5
years after eSRT according to cancer characteristics at RP.
Results: Median follow-up after eSRT was 47 months. The 5-
year BCR-free survival rate was 81%. At multivariable
analysis, pre-eSRT PSA level was associated with BCR after
eSRT (hazard ratio (HR)=4.89; p<0.0001). Moreover,
pathologic stage ≥pT3b (HR=2.07; p=0.007), pathologic
Gleason score ≥8 (HR=2.69; p=0.0002) and negative surgical
margins (HR=2.50; p<0.0001) were associated with BCR and
were identified as risk factors. Overall, using lowess methods,
we observed a decrease of 5-year BCR-free survival rate from
87% to 75% for pre-eSRT PSA level ranging from 0.1ng/ml to
0.5 ng/ml. Overall, the 5-year BCR risk increased by 3% per
0.1 ng/ml of PSA level. However, when patients were
stratified according to the number of risk factors (≤1 vs. ≥2),
the effect of increasing PSA at eSRT on cancer control was
higher in men with more aggressive disease. Specifically,
patients with ≥2 pathologic risk factors showed a 5-year
increased risk of BCR equal to 10% per 0.1 ng/ml of PSA
level vs. 1.5% in patients with a single risk factor (p<0.001).
Conclusion: Cancer control after eSRT depends on
pretreatment PSA level. This effect is highest in men with, at
least, two of the following features: pT3b/pT4 disease,
pathologic Gleason score ≥8 and negative surgical margins. In
these patients, eSRT should be administered at the very first
sign of PSA increase in order to maximize cancer control.
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Figure 1. (Abstract 115).
Case Report: A 47-year-old patient was referred to our centre
for gross hematuria, mild dysuria and other lower urinary tract
symptoms (LUTS). Past medical history was unremarkable and
no co-morbidities were present. Digital rectal examination
(DRE) revealed, cranially to the prostate, a tense-elastic mass
with undefined upper and lateral boundaries. Prostate-specific
antigen (PSA) level was 1.7 ng/ml. Physical examination and
laboratory tests were otherwise normal. Trans-abdominal
ultrasound showed no lesions or abnormalities in the upper
urinary tract; high-resolution trans-rectal ultrasound (TRUS)
confirmed the presence of a multisepted, solid-cystic pelvic mass
occupying the retrovesicle space. An office cystoscopy showed
no lesions within the bladder. Pelvic magnetic resonance
imaging (MRI) confirmed the presence of a retrovesicle, 6.0×4.5
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Table I. Strategies for diagnosis and types of surgical approach for seminal vesicle cystoadenoma according to the published series. TRUS,
transrectal ultrasound; CT, computed tomography; MRI, magnetic resonance imaging; CYS, cystoscopy; FNA, fine needle aspiration; Abd
US, abdominal ultrasound, RALV, robot-assisted laparoscopic vesiculectomy.
Study Patient’s Tumor size Diagnostic Surgical Perioperative Local recurrence, 
age (greatest strategy procedure complication Y=present, 
(years) diameter) Y=present, N=absent 
(cm) N=absent (years after 
surgery)
Soule et al. Proc Staff 47 14 Open N N
Meet Mayo Clin., 1951. (Conservative)
Damjanov et al. J Urol., 1974. 52 5.5 Autopsy N N
Lundhus et al. Scand J 39 7.4 Open N N
Urol Nephrol., 1984. (Cysto-prostato-
vesiculectomy)
Mazur et al. Am Jour 49 7 Open N Y (2)
of Surg Path 1987. (Conservative)
Bullock et al. JR Soc Med., 1988. 59 12 LV N Y (3)
Raghuveer et al. Indian J 
Pathol Microbiol., 1989.
Mazzucchelli et al. J Urol., 1992. 63 3 Open N N
(Conservative)
Ranschaert et al. J Belge 50 12 Open N N
Radiol., 1992. (Conservative)
Lagalla et al. Abdom Imaging 1993. 33 TRUS, CT, FNA - Open N N
Cytology, Biopsy (Conservative)
Santos et al Pathology., 2001. 49 15 Open N N
(Conservative)
Gil et al International Braz 49 7 Abd US, CT, MRI Open N N
J Urol., 2003. (Conservative,
retrovesicle 
approach)
Lee et al. Intern Jour  46 7.5 CT, MRI, Explorative Open N N
of Urol., 2006. Laparotomy (Conservative)
Lorber et al Eur Urol., 2011. 52 14 CT, MRI, Abd Open N N
US, Biopsy (Conservative, 
transvesicle)
Kural et al. Journ of Endourol., 2011. 48 6 TRUS, Biopsy RALV N N
Ploumidis et al. Intern Jour 45 17.2 TRUS, CT, MRI, CYS, RALV N N
of Surg Case Reports 2012. FNA-Cytology, Intra-
operative Biopsy
Arora et al. Urology 2013. 23 TRUS, MRI Open N N
(Conservative)
Zhu et al. Asian Journ of 31 5 CT, MRI LV N N
Andrology 2013. 
Zhang et al. Urology 2013. 32 5 LV N N
Zhang et al. Urology 2013. 64 4.5 LV N N
Zhang et al. Urology 2013. 50 3.8 LV N N
cm well-defined pseudo-nodular mass, arising from the right
seminal vesicle (SV) and vas deferens (VD) (Figure 1).
TRUS-guided prostatic and SVs biopsies showed no
neoplastic proliferation in all the samples from both the
prostate and the mass. The patient was then scheduled for
robot-assisted laparoscopic vesiculectomy (RALV). After a
transversal incision of the peritoneum at the level of the
Douglas pouch, a voluminous mass, firmly adherent to the
surrounding tissues, was found. The plane between the mass,
the rectum and the bladder was carefully developed until the
tumor was completely released from the surrounding
adhesions. The left VD and SV were preserved during the
dissection. The neuro-vascular bundles (NVBs) were
approached bilaterally in an athermal, traction-free manner in
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Figure 2. (Abstract 115).
Figure 3. (Abstract 115).
order to preserve continence and potency. The specimen was
then removed intact through the camera port by using a
retrieval bag. Accurate hemostatic control was achieved and a
tube drain was positioned. Console time and estimated blood
loss were, respectively, 120 minutes and 50 cc; no
intraoperative complications were recorded. The post-
operative course was uneventful and the patient was
discharged on the fourth postoperative day with normal blood
tests and spontaneous voiding. A two-year follow-up showed
no evidence of disease recurrence. At present, the patient is
free of symptoms with full preservation of continence and
potency. Histopathological examination revealed a
7.0×4.5×4.5 cm cystic SV cystoadenoma (Figure 2). 
No significant cytologic atypia, mitotic activity or necrosis
were present. The proliferation index was <1%. Review of
the Literature: A systematic review of the English-language
literature was performed using the Medline, Embase and
Web of Science databases up to December 2014. Twenty
case reports have been published in literature on SV
cystoadenoma (Table I). 
Median patient age and median tumor diameter were 49
years (inter-quartile range (IQR)=42-51) and 7.0 cm (IQR
5.0-12.0), respectively. No perioperative complications were
reported in all the published series. Local recurrence
occurred in 2 cases (10%) after 2 and 3 years, respectively.
The differential use of diagnostic investigations and surgical
approaches for SV cystoadenoma in the published series is
shown in Figure 3. Discussion and Conclusion: Primary
tumors of SVs are very rare and the differential diagnosis
must be based on a multimodality approach. Most cases of
SV cystoadenoma were managed with open surgery through
transvesicle/retrovesicle approaches or radical cysto-prostato-
vesiculectomy. To date, minimally-invasive seminal
vesiculectomy (MISV) is increasingly used for the treatment
of beginning diseases of SVs achieving optimal oncologic
and functional results. Therefore, they could be considered
the new gold standard for the treatment of such rare diseases.
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Introduction/Aim: Benign tumors (BT) of seminal vesicles (SV)
are very rare. Diagnosis could be challenging and often requires
the histopathological analysis after surgical excision. The best
surgical treatment is still matter of discussion. The aim of this
review is to analyze the current strategies for diagnosis and
treatment of such tumors. Materials and Methods: A systematic
review of English literature was performed using the Medline,
Embase and Web of Science databases up to October 2014. Use
of diagnostic investigations, options of surgical management,
perioperative complications rate and oncologic outcomes were
analyzed for each tumor histotype. Results: Fifty-eight case
reports have been published in literature on BTs of SVs (Table I).
Of these, 5 were excluded from the analysis due to lack of data.
Cystoadenoma was found in 20 cases (38%), leiomyoma in 10
(19%), schwannoma in 8 (15%), mixed epithelial-stromal tumor
in 5 (9%), phyllodes tumor in 4 (8%) and other BTs in 6 (11%)
(Figure 1). Median patient age and median tumor diameter were
50 years (range=23-79) and 5.0 cm (range=2.0-29.0),
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Figure 1. (Abstract 116).
